Illumina Expands Goldengate® Genotyping Portfolio
Complete the form below to unlock access to ALL audio articles.
Illumina, Inc. has announced the commercial availability of three GoldenGate® single nucleotide polymorphism assay panels designed to study genetic variation and help researchers understand how certain genotypes impact disease.
Illumina has also introduced a 96-plex Sentrix® universal array, further expanding the multiplexing flexibility of custom GoldenGate genotyping. Supplementing the catalog offerings is a test panel to screen DNA samples for predictive assay quality.
Developed in collaboration with the National Cancer Institute, Illumina's Cancer SNP Panel can genotype 1421 loci on over 400 genes thought to be related to disease progression.
As a result of the implementation on the Sentrix Array Matrix format, 96 samples are analyzed in parallel.
This panel is designed to give cancer researchers an effective tool for conducting candidate gene-based association studies across many samples.
Mouse has evolved as an optimal model system for investigating the genetics of complex disease traits. For instance, a SNP in a gene that helps determine bone mineral density would be expected to associate strongly with osteoporosis.
Illumina has developed two mouse linkage panels for high-throughput and informative GoldenGate genotyping. The first panel includes 377 validated SNP loci optimized for the 10 most common inbred mouse strains used in genetic mapping.
The second panel (1449 loci) is designed to provide higher resolution and broader mapping capability, enabling linkage analysis in outbred strains as well. The panels are profiled online.
"Customers will find it very easy to integrate these SNP panels into their BeadStation genotyping operations," explains Sarah Shaw Murray, Ph.D., Staff Genotyping Science Manager.
"Typical of GoldenGate genotyping, data quality is extremely high. In addition, customers will be able to access the data either from our fast-track genotyping service or as part of a genotyping reagent kit."
In response to customers who want to study smaller numbers of validated SNP markers per sample, Illumina has also introduced Sentrix universal arrays that contain a multiplex level of just 96 GoldenGate assays.
This advancement now allows customers flexibility to genotype sets of custom markers ranging from 96 to 1536 SNPs per array, depending on their application and need.
Finally, Illumina has developed and made available a GoldenGate DNA Test Panel composed of 360 markers that reside outside of genes and conserved sequences and are likely to be "neutral" to disease association.
This panel can be used to selectively pre-screen sample DNA quality prior to embarking on a large-scale genotyping study.
"We're very pleased to introduce these powerful new genotyping tools," stated Jay Flatley, Illumina President and CEO. "Our expanded portfolio of standard products will help deliver additional value into our growing base of users."
"Additionally, the pace of our new product launches underscores the capabilities of our core manufacturing operations and the ever-improving execution skill of our development teams."
Illumina's genotyping product portfolio includes custom and standard products, with focused and whole-genome content, deployed on two different array platforms: the 96-sample Sentrix Array Matrix and the high-density Sentrix BeadChip.
